Most ACC patients, despite phenotype distinction, were in the top third group for expression of CD276 (B7-H3), GPC1, vascular endothelial growth factor A (VEGFA), vascular endothelial growth factor B (VEGFB), and vascular endothelial growth factor receptor 1 (VEGFR1) FLT1 (Figure 7B). This evidence concerns the gene VEGFB and adrenal cortex carcinoma.